Fabtech Technologies Cleanrooms IPO: The allotment status of Rs 27.74 crore SME IPO is out for shareholders to review. On January 9, the eligible investors will receive the equity shares in their demat account. The latest grey market premium (GMP) of Fabtech signals a whopping 123.5% premium listing on BSE. The IPO will not debut on NSE.
Fabtech Technologies Cleanrooms IPO Allotment:
There are two ways to check the allotment status of Fabtech Technologies IPO. These are BSE and the registrar of the IPO, Maashitla Securities Private Limited.
To check the application status on BSE, click on the link below:
As per Investor Grain, Fabtech Technologies SME IPO last GMP is ₹105, last updated Jan 9th 2025 05:04 AM. With a price band of 85.00, Fabtech Technologies SME IPO's estimated listing price is ₹190 (cap price + today's GMP). The expected percentage gain/loss per share is 123.53%.
What is GMP? As per Nirmal Bang website, Grey Market IPO is an unofficial market where individuals buy/sell IPO shares or applications before they are officially launched for trading on the stock exchange. As it is an unofficial over-the-counter market, there are no regulations around it. All transactions are done in cash on a personal basis. Any 3rd party firms like SEBI, Stock Exchange or Brokers are not involved or back this transaction. Grey market trading is done among the small set of people as there is no official platform or rules defined for these trading. Two popular terms used in the IPO grey market are 'Grey Market Premium' and ' Kostak'.
Fabtech Technologies Cleanrooms IPO Details:
The IPO had opened for subscription from January 3rd to January 7th. It carried its allotment status on January 8th accordingly. Subscription was carried at a price of Rs 80 to Rs 85 per share of a total size of 32,64,000 equities. By the end of the final day, the IPO received massive demand with an oversubscription of 740.37 times.
The IPO will be listed on January 10th.
About Fabtech Technologies Cleanrooms:
Fabtech is a leading transnational pharmaceutical engineering company headquartered in Mumbai, India with regional offices in Dubai (UAE), Saudi Arabia, Egypt, Nigeria, the UK, Algeria, and Sri Lanka.
Over the last 25 years, the company built up a stellar reputation for delivering specialised start-to-finish (turnkey) solutions for Pharmaceutical, Biotechnology and Healthcare companies all over the globe. With over 750 projects in 62 countries, Fabtech has positively influenced the lives of 73 million individuals, establishing itself as a powerhouse of life engineering!
For investment related articles, business news and mutual fund advise
Click it and Unblock the Notifications
Sign in with Google